US › Healthcare

Plus Therapeutics Inc (PSTV)

US · Healthcare · Biotechnology

—

Latest quarter · ended 2026-06-30

Revenue

$411,000

Revenue YoY

-70.4%

Net profit

$-9.0M

Profit YoY

-274.8%

EPS

$-1.05

EPS estimate

$-0.87

Net margin

-2,191.2%

EPS came in at -1.05 against a street estimate of -0.87 — a miss of 20.7%.

Key statistics

Market cap

$26.6M

P/E

0.2

Forward P/E

1.0

P/B

3.75

Book value

$1.74

EPS (TTM)

$21.56

52-week high

$23.43

52-week low

$2.90

50-day MA

$4.30

200-day MA

$7.84

Beta

1.42

Analyst view

Analysts rate Plus Therapeutics Inc a buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $36.00.

Shareholding

Insiders

1.84%

Institutions

13.87%

Largest institutional holders

Fund	Stake
Geode Capital Management, LLC	1.17%
BlackRock Inc	1.03%
State Street Corp	0.27%
Northern Trust Corp	0.17%
XTX Topco Ltd	0.07%
Citigroup Inc	0.05%
UBS Group AG	0.05%
CAMBRIDGE Invest RESEARCH ADVISORS, INC.	0.01%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Plus Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.